Connect with us

Technology

Pharmaceutical Contract Research and Manufacturing Market to grow by USD 141.3Billion from 2024-2028, driven by cost-efficient resources in emerging markets, AI-powered report – Technavio

Published

on

NEW YORK, Oct. 7, 2024 /PRNewswire/ — Report on how AI is driving market transformation – The Global Pharmaceutical Contract Research and Manufacturing Market size is estimated to grow by USD 141.3 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  10.87%  during the forecast period. Availability of cost-efficient resources in emerging markets is driving market growth, with a trend towards increasing number of US FDA approved manufacturing facilities. However, stereotypical nature of CMOS  poses a challenge – Key market players include Almac Group Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Catalent Inc., Charles River Laboratories International Inc., Cmic Holdings Co. Ltd, Dr Reddys Laboratories Ltd., ICON plc, IQVIA Holdings Inc., Laboratory Corp. Of America Holdings, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, OPTIMAPHARM d.o.o., Parexel International Corp., PCI Pharma Services, Recipharm AB, Samsung Electronics Co. Ltd., Syneos Health Inc., and Thermo Fisher Scientific Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report

Pharmaceutical Contract Research And Manufacturing Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 10.87%

Market growth 2024-2028

USD 141.3 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

9.51

Regional analysis

North America, Asia, Europe, and Rest of World (ROW)

Performing market contribution

Asia at 46%

Key countries

US, China, India, Germany, and UK

Key companies profiled

Almac Group Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Catalent Inc., Charles River Laboratories International Inc., Cmic Holdings Co. Ltd, Dr Reddys Laboratories Ltd., ICON plc, IQVIA Holdings Inc., Laboratory Corp. Of America Holdings, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, OPTIMAPHARM d.o.o., Parexel International Corp., PCI Pharma Services, Recipharm AB, Samsung Electronics Co. Ltd., Syneos Health Inc., and Thermo Fisher Scientific Inc.

Market Driver

The Pharmaceutical Contract Research and Manufacturing (CRAM) market is experiencing significant growth due to the increasing number of US FDA-approved manufacturing facilities in emerging economies, particularly China and India. India, with around 400 such facilities, is a top destination for pharmaceutical manufacturing services outsourcing. This includes approximately 230 API and 150 FDF facilities, the highest in any country. China, previously limited to CROs due to stringent regulations on CMOS, has seen a shift with the State Council allowing MAHs to use third-party licensed manufacturers. This change has led to an increase in US FDA-approved facilities and foreign pharmaceutical companies outsourcing drug manufacturing to China. This trend is expected to continue, driving the growth of the global pharmaceutical CRAM market.

The Pharmaceutical Contract Research and Manufacturing (CRM) market is witnessing significant trends in various areas. Generic Drugs are gaining popularity due to their affordability, driving demand for Generic APIs and Formulation Services. Artificial Intelligence is revolutionizing Drug Discovery and Development, enabling faster identification of Drug Candidates. Route Scouting Services and Bioprocess Outsourcing are key areas of focus for Biologics Manufacturing. Regulatory Compliance remains a top priority, with Serialization and Counterfeiting mitigation measures essential. Clinical Trials are outsourced to CROs for cost-effective manufacturing and efficient Clinical Operations. Big Pharmaceutical Companies and Academic Institutes collaborate for innovative Drug Development Services. Advanced manufacturing technologies like Continuous Manufacturing and Digitalization are transforming the Pharmaceutical Ecosystem. Targeted Medication Therapies, Biosimilars, and Personalized Medicines are driving the need for Specialized Services and Cost-effective Manufacturing. Drug Delivery Systems and Clinical Trial Support are crucial for bringing Small Molecule Drugs and Active Pharmaceutical Ingredients to market. Regulatory bodies and industry associations play a vital role in ensuring Quality Control and ensuring the integrity of the Pharmaceutical Supply Chain. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

The pharmaceutical Contract Research and Manufacturing Organizations (CMOs) market in the Asia Pacific region holds the largest share but faces a significant challenge due to limited access to advanced technologies for manufacturing complex drugs, such as biological drugs and vaccines. These CMOs primarily focus on producing small molecule-based generic drugs due to high manufacturing costs and lack of funding. This restricts growth opportunities for small and medium-sized CMOs. Major players like Boehringer Ingelheim, Catalent, and Lonza dominate the market for large-scale production of biological drugs. The absence of advanced technologies and high manufacturing costs in countries like Mexico, South Korea, and Brazil also hinder the growth of CMOs in these regions. Consequently, the global pharmaceutical CRAM market growth may be impeded substantially during the forecast period.The Pharmaceutical Contract Research and Manufacturing (CRM) market faces several challenges in the production of biologics and small molecule drugs. Big Pharma companies and academic institutes rely on CROs for cost-effective manufacturing of targeted medication therapies, including biologics and biosimilars. Manufacturing services for active pharmaceutical ingredients (APIs) and drug formulation require advanced technologies like continuous manufacturing and specialized services for drug delivery systems. Quality control is crucial for producing consistent, high-quality products. CROs must support clinical trial operations and commercial operations, ensuring compliance with quality standards and patient needs. Digitalization and personalized medicines also require specialized expertise. The drug development process involves complex production workflows, from the creation of drug candidates to the manufacturing of oral solids, liquids, emulsions, and more. Meeting the demands of Big Pharma and academic institutes while maintaining cost-effectiveness and quality is a significant challenge for the CRM industry.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview

This pharmaceutical contract research and manufacturing market report extensively covers market segmentation by

Service 1.1 CMO1.2 CROEnd-user 2.1 Big pharmaceuticals2.2 Small and medium-sized pharmaceuticals2.3 Generic pharmaceuticalsGeography 3.1 North America3.2 Asia3.3 Europe3.4 Rest of World (ROW)

1.1 CMO-  The Contract Research and Manufacturing Organizations (CMOs) segment is the largest in the global pharmaceutical CRAM market, accounting for a significant market share. CMOs are entities that manufacture drugs and healthcare products on a contract basis for pharmaceutical companies and biotech firms. Advancements in medical sciences and the growing popularity of specialty medicines, as well as technological developments like nanotechnology and stem cell research, are driving the demand for complex manufacturing processes. These processes require extended resource deployments, leading pharmaceutical giants like Pfizer, Johnson & Johnson, and GlaxoSmithKline to outsource their manufacturing activities to optimize in-house resources. The outsourcing trend is particularly prevalent among pharmaceutical vendors worldwide, resulting in the substantial growth of the CMO segment. Emerging markets, including India, Brazil, China, and Mexico, are major contributors due to their low labor and land costs, making them attractive locations for setting up manufacturing facilities. Generic drug manufacturers in these countries outsource approximately 80% of their production to CMOs. The increasing focus on core competencies and cost reduction, along with the regulatory compliance and research advancement benefits, are fueling the expansion of the CMO segment in the global pharmaceutical CRAM market.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

The Pharmaceutical Contract Research and Manufacturing (CRM) market encompasses a range of services that support the development and production of small molecule drugs, biologics, biosimilars, and active pharmaceutical ingredients (APIs). Services include drug discovery, route scouting, regulatory compliance, clinical trials, outsourcing, drug formulation, quality control, and advanced manufacturing technologies such as continuous manufacturing and specialized services. Artificial Intelligence (AI) is increasingly being utilized in drug discovery to identify new drug candidates and optimize their properties. Cost-effective manufacturing is a key driver for outsourcing, particularly for generic drugs and APIs. Bioprocess outsourcing is essential for the production of complex biologics and biosimilars. Continuous manufacturing offers advantages in terms of cost savings, improved quality, and increased efficiency. Specialized services include the production of low potent APIs and the manufacturing of originator and generic APIs. The market caters to both small molecule drugs and biologics, with a focus on ensuring regulatory compliance and maintaining the highest standards of quality control.

Market Research Overview

The Pharmaceutical Contract Research and Manufacturing (CRM) market encompasses a range of services that support the entire drug development process, from discovery to commercialization. This market includes various services such as drug discovery, clinical trials, regulatory compliance, route scouting, bioprocess outsourcing, and manufacturing services. Generic Drugs: CRM companies offer manufacturing services for generic drugs, producing affordable alternatives to branded medicines. Artificial Intelligence: AI is increasingly used in drug development to identify new targets, optimize drug design, and analyze clinical trial data. Drug Development: CRM companies provide comprehensive drug development services, from discovery to commercialization, ensuring regulatory compliance and cost-effective manufacturing. Clinical Trials: CRM companies offer clinical trial support, managing trial design, execution, and data analysis to ensure efficient and effective trials. Outsourcing: Pharmaceutical companies outsource various aspects of drug development and manufacturing to CRM companies for cost savings and expertise. Bioprocess Outsourcing: CRM companies specialize in bioprocessing, producing biologics, biosimilars, and vaccines using advanced manufacturing technologies. Serialization and Counterfeiting: CRM companies provide serialization services to ensure product authenticity and combat counterfeiting, enhancing patient safety. Pharmaceutical Ecosystem: CRM companies operate within the complex pharmaceutical ecosystem, collaborating with academic institutes, CROs, and big pharma to bring new drugs to market. Drug Development Services: CRM companies offer a range of drug development services, from drug discovery and formulation to manufacturing and commercialization. Manufacturing Services: CRM companies provide manufacturing services for small molecule drugs, APIs, and drug delivery systems, ensuring quality control and cost savings. Cost-effective manufacturing: CRM companies offer cost-effective manufacturing solutions, utilizing economies of scale and advanced technologies to reduce production costs. Quality control: CRM companies prioritize quality control, implementing rigorous standards and advanced technologies to ensure product safety and efficacy. Advanced manufacturing technologies: CRM companies employ advanced manufacturing technologies, such as continuous manufacturing and specialized services, to improve efficiency and reduce costs. Personalized medicines: CRM companies support the development and manufacturing of personalized medicines, tailoring treatments to individual patient needs. Drug development processes: CRM companies optimize drug development processes, from production workflows to digitalization, to bring new drugs to market faster and more efficiently.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ServiceCMOCROEnd-userBig PharmaceuticalsSmall And Medium-sized PharmaceuticalsGeneric PharmaceuticalsGeographyNorth AmericaAsiaEuropeRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmaceutical-contract-research-and-manufacturing-market-to-grow-by-usd-141-3billion-from-2024-2028–driven-by-cost-efficient-resources-in-emerging-markets-ai-powered-report—technavio-302267668.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

CasinoPartiesLLC.com Expands Premier Casino Party Rentals in Manhattan, NY — Authentic Tables, Professional Dealers, Custom Packages for Corporate & Private Events

Published

on

By

Top-rated Manhattan casino party rental company offers fully staffed blackjack, roulette and craps experiences to elevate corporate events, weddings and private parties across New York City

MANHATTAN, N.Y., May 2, 2026 /PRNewswire-PRWeb/ — CasinoPartiesLLC.com, a leading provider of casino party rentals in Manhattan, NY, today announced expanded availability and new customizable event packages for corporate events, private parties, fundraisers and weddings throughout New York City. With authentic casino tables, professional and entertaining dealers, premium play-money chips and signage, CasinoPartiesLLC.com delivers a turnkey casino entertainment experience that brings the excitement of Las Vegas to Manhattan venues.

“CasinoPartiesLLC.com delivers authentic casino table rentals and professional dealers throughout Manhattan, NY — offering turnkey, customizable packages that transform corporate events, weddings and fundraisers into high‑energy, engaging experiences across Midtown, Chelsea and the Upper East Side.”

Focused on delivering safe, legal and memorable experiences, CasinoPartiesLLC.com offers:

Casino table rentals: blackjack, roulette, craps, poker tables sized for intimate and large gatheringsProfessional dealers and croupiers trained in guest interaction and game managementFully customizable packages: themed décor, tournament-style play, prize support, and multi-table setupsPortable, all-inclusive service: setup, teardown, on-site management, and event coordinationService across Manhattan neighborhoods and greater NYC, including Midtown, Upper East Side, Chelsea, and downtown venues

“Our Manhattan clients want authentic casino entertainment without the hassle of sourcing equipment or personnel,” said Ismael Qureshi, CEO of CasinoPartiesLLC.com. “We specialize in seamless casino party rentals in Manhattan, NY, providing professional dealers and tailored packages that fit corporate budgets and private event needs while complying with local regulations.”

Benefits for Manhattan event planners and hosts:

Boost guest engagement with interactive casino entertainmentEasy logistics with single-vendor solutions for gaming, staffing and prize handlingScalable options for small private parties to large corporate galasProven experience executing events in Manhattan hotels, event spaces and private residences

Booking and availability:

CasinoPartiesLLC.com is currently accepting bookings for summer and fall events across Manhattan and greater New York City. Early reservations are recommended to secure preferred dates, table counts and themed packages.

About CasinoPartiesLLC.com:

CasinoPartiesLLC.com is a premier provider of casino party rentals in Manhattan, NY and the New York City area. Specializing in staffed casino tables, custom event packages and professional service, CasinoPartiesLLC.com helps event planners and hosts create high-energy, memorable experiences for corporate functions, weddings, fundraisers and private celebrations. For more information or to request a quote, visit https://www.CasinoPartiesLLC.com.

Media contact:

Ismael Qureshi

President

CasinoPartiesLLC.com

Phone: (917) 829-8481

Email: Sales@casinopartiesLLC.com

Website: https://www.CasinoPartiesLLC.com

Media Contact

Ismael Qureshi, ISH Events LLC, 1 (917) 829-8481, Ismael@CasinoPartiesLLC.com, CasinoPartiesLLC.com

View original content to download multimedia:https://www.prweb.com/releases/casinopartiesllccom-expands-premier-casino-party-rentals-in-manhattan-ny–authentic-tables-professional-dealers-custom-packages-for-corporate–private-events-302760531.html

SOURCE CasinoPartiesLLC.com

Continue Reading

Technology

PS Hogan highlights investments from Spring Economic Update 2026: Canada Strong for All to support Canada’s sport system

Published

on

By

CALGARY, AB, May 2, 2026 /CNW/ – In Budget 2025, we outlined our plan to build Canada Strong. Since then, we have moved fast to build the major infrastructure, homes and industries that grow Canada’s economy and create lasting prosperity; empower Canadians with better careers and a more affordable life; and protect our communities, our borders and our way of life.

We delivered concrete savings for Canadians while supporting key national priorities and keeping investments focused on results. We are maintaining a strong fiscal position, with the Spring Economic Update 2026 showing that projected deficits are lower over the fiscal horizon and that we are on track to meet our fiscal anchors.

The Spring Economic Update 2026 is the next step in our plan to build Canada Strong for All. It provides a clear update on the strength of Canada’s economy, giving Canadians confidence in our plan. It delivers targeted relief to make life more affordable, support workers and accelerate the construction of homes and major infrastructure. It also strengthens Canada’s competitiveness and economic growth while investing in strong, safe communities across the country.

Today, Corey Hogan, Parliamentary Secretary to the Minister of Energy and Natural Resources and Member of Parliament for Calgary Confederation, met with athletes at Foothills Athletic Park to highlight key investments in sport from the Spring Economic Update to build stronger and safer communities.

The Government of Canada is investing $755 million to support and expand Canada’s sport system, which will help athletes safely train and perform at the highest levels. This will increase sport participation across the country by strengthening national sport organizations, infrastructure and local sport communities.

Canada’s new government is transforming our economy from reliance to resilience. The Spring Economic Update 2026 ensures all Canadians can participate in building Canada strong and share in its success. Other key measures include:

The Canada Strong Fund — Canada’s first national sovereign wealth fund. This will invest in key, strategic Canadian projects and companies. While Canadians will benefit from these nation building projects through jobs, economic growth and greater security, the government is determined to ensure that Canadians also have a stake in the projects themselves. That’s why a unique and important feature of the Canada Strong Fund will be its new retail investment product. This allows Canadians to receive financial returns as we build Canada strong together.Team Canada Strong — a new nationwide effort to recruit, train and hire 80,000 to 100,000 new skilled trade workers by 2030–31. This initiative creates new opportunities for Canadians and attracts the workers needed to build more homes and major projects at speed and at scale.Building Stronger Communities — by making communities safer, more connected and more resilient. We are building more homes, getting tougher on crime and fraud and funding essential infrastructure, including small craft harbours that sustain coastal communities and local jobs. We are also investing to build healthier, safer and stronger Indigenous communities.

Our new government is building a Canada that is not just strong, but good; not just prosperous, but fair. A Canada that is not just for some, most of the time, but for all, at all times. We’re building Canada strong, for all.

Quote

“The Spring Economic Update 2026 builds on the momentum of our budget, combining strategic investments with sustained fiscal discipline to keep building Canada Strong for All — delivering prosperity today and strengthening our economy for tomorrow. At this pivotal moment in Canada’s history, we’re charting a course through the fog of uncertainty and global headwinds with strength, determination and ambition — and building one strong Canadian economy, by Canadians, for Canadians.”
— The Honourable François-Philippe Champagne, Minister of Finance and National Revenue 

“The Government of Canada is building Canada Strong by investing in what brings us together — our people, our communities and our athletes. By strengthening the foundation of Calgary and  Canada’s sport system, we are building a resilient economy and strong communities for all.”
— Corey Hogan, Parliamentary Secretary to the Minister of Energy and Natural Resources and Member of Parliament for Calgary Confederation

Quick Facts

The Spring Economic Update 2026 proposes to provide $755 million over five years, starting in 2026–27, and $118 million ongoing to Canadian Heritage to support Canada’s sport system to: Host and compete with the best: $50 million over five years to bring more world-class sporting events to Canada. Funding will be tied to legacy-building projects that deliver lasting benefits well beyond the events themselves. Facilities built or upgraded for major events will continue to serve communities, support grassroots participation and strengthen local sport systems for years to come. Support our athletes in performing at the highest levels: $45 million over five years and $8 million ongoing to help our athletes train, compete and perform, including support for better mental health and funding that will be linked to robust safe sport measures and frameworks. These actions will strengthen the sport system and respond to some of the findings of the Final Report of the Future of Sport in Canada Commission while the government continues to consider all of its Calls to Action. Get more Canadians involved in sport: $660 million over five years and $110 million ongoing for National Sport Organisations, increasing funding that has remained largely unchanged since 2005, so that they can invest in a strong and safe sport system and grow participation among children and youth nationwide.

Related products

Spring Economic Update 2026: Canada Strong for AllSpring Economic Update 2026: Key MeasuresSpring Economic Update 2026: Address by the Minister of Finance and National Revenue  

Follow Natural Resources Canada on LinkedIn

SOURCE Natural Resources Canada

Continue Reading

Technology

POVADDO AND PROLEGIS ANNOUNCE STRATEGIC PARTNERSHIP TO EXPAND ACCESS TO PUBLIC POLICY PROFESSIONALS FOR OPINION RESEARCH

Published

on

By

Partnership connects policy professionals using Prolegis’ modernized Congressional platform with Povaddo’s exclusive paid research panel, combining forces to serve the policymaking community

ST. LOUIS and WASHINGTON, May 2, 2026 /PRNewswire/ — Povaddo, a leading provider of public opinion and policy elite research, has announced a strategic partnership with Prolegis, a nonpartisan technology platform serving thousands of policy professionals in Congress and the advocacy community. The partnership will expand the reach of the Povaddo Panel—an exclusive network of nearly 5,000 public policy professionals worldwide—while providing Prolegis users new opportunities to contribute their expertise to policy research.

Prolegis provides nonpartisan technology solutions designed to modernize Congress. Built specifically for the policymaking community, the platform serves as a natural intersection where policy professionals and issue advocacy campaigns meet, making it an ideal environment for connecting researchers with the experts shaping public policy.

Beginning this month, users of the Prolegis platform will be invited to join the Povaddo Panel and become eligible to participate in research studies tailored specifically for public policy professionals.

“There is no shortage of so-called ‘expert network’ firms, but Povaddo is setting the standard when it comes to building the most rigorous and credible network of public policy professionals in the U.S. and beyond,” said William Stewart, President of Povaddo. “What makes Prolegis the right partner is the quality and relevance of their community—these are precisely the professionals our clients most want to hear from. Prolegis users are actively engaged in policy work daily, making them ideal participants for our research studies. This partnership will meaningfully accelerate our efforts.”

“Prolegis exists to serve the policy community with tools that make their work more effective,” said Jim Gianiny, CEO of Prolegis. “Partnering with Povaddo allows our users to contribute their expertise in a new way and take part in rigorous research that helps organizations better understand the policy landscape. It’s a natural extension of what our platform already does: connecting policy professionals with the resources and opportunities that matter to their work.”

Launched in 2018, the Povaddo Panel was built to meet growing demand for research insights from individuals who shape, influence, and analyze public policy as part of their daily work. Over the past eight years, the panel has grown to nearly 5,000 public policy professionals worldwide, including over 2,000 in the United States. Many panelists are former elected officials, including former Members of Congress.

This partnership is part of a broader period of momentum for Povaddo. The company recently announced it is launching a quarterly omnibus survey among public policy professionals in the United States and Europe.

“Companies and other organizations that want to understand what public policy professionals think—whether about their brand or an issue they are facing—now have a new way of doing that. Our new omnibus survey among public policy professionals fills an important need in the research services marketplace,” said Brooke Hayes, Executive Vice President of Povaddo, who oversees the Povaddo Panel and the firm’s new omnibus research service among public policy professionals.

Additionally, Povaddo recently released select findings from its survey of public policy professionals in the U.S. and Europe regarding their attitudes towards AI. In an era when political consensus is elusive, this study finds widespread agreement within policy communities on both sides of the Atlantic that government regulation of AI should be increased.

About Povaddo: Povaddo specializes in public opinion and policy elite research. Founded in 2009, Povaddo is recognized as a trusted advisor to top-tier organizations seeking to navigate complex issues management, strategic communications, corporate reputation, and business transformation challenges. Most of the firm’s clients sit within external affairs, corporate affairs, public affairs, government affairs, regulatory affairs, scientific affairs, corporate communications, business planning and strategy. For more information, please visit www.povaddo.com.

About Prolegis: Prolegis provides nonpartisan technology solutions designed to modernize Congress. Built specifically for the policymaking community, Prolegis delivers innovative solutions, efficient tools, and engaging content, all on one easy-to-use platform. The platform serves Congressional staff, think tank scholars, and public affairs professionals, creating a unique intersection where policy expertise and advocacy meet. For more information, please visit www.prolegis.com.

Media Inquiries: William Stewart, +1 (855) 768-2336, stewart@povaddo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/povaddo-and-prolegis-announce-strategic-partnership-to-expand-access-to-public-policy-professionals-for-opinion-research-302760432.html

SOURCE POVADDO LLC

Continue Reading

Trending